Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › natalizumab

natalizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of natalizumab

10 trials tracked of natalizumab: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 113 citations.

10Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 7
  1. Phase 3 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration Completed · 113 cited
  2. Phase 4 Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis Completed
  3. Phase 4 Natalizumab De-escalation With Interferon Beta-1b Completed
  4. Phase 2 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Completed
  5. Phase 2 Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis Completed
  6. Phase 2 Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD Completed
Show 4 more trials
  1. Phase 2 Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke Completed
  2. Phase 2 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy Completed
  3. Phase 2 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke Completed
  4. Phase 2 Treatment Interruption of Natalizumab Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Extended-interval natalizumab dosing shows no significant difference in disability progression for relapsing-remitting multiple sclerosis
Neurology Meta-analysis
Extended-interval natalizumab dosing shows no significant difference in disability progression for relapsing-remitting multiple sclerosis Extended dosing of natalizumab shows similar outcomes for multiple sclerosis
This meta-analysis of patients with relapsing-remitting multiple sclerosis found that extended-interval dosing (EID) of natalizumab did not …
New data suggests that spacing out natalizumab doses may work as well as standard schedules for patients with relapsing-remitting multiple s…
Jul 3, 2026
Cladribine tablets reduce annualized relapse rate by 58% compared to placebo in active RRMS
Neurology Sys. Review
Cladribine tablets reduce annualized relapse rate by 58% compared to placebo in active RRMS Cladribine tablets show promise for managing relapsing-remitting multiple sclerosis
This systematic review and network meta-analysis of 66 studies evaluated cladribine against various disease-modifying treatments for relapsi…
New data shows cladribine tablets significantly reduce relapse rates and slow disease progression in people with active relapsing-remitting …
Jul 1, 2026